DSM Biologics and Crucell N.V. Announce PER.C6(R) Licensing Deal With LFB Biotechnologies

LEIDEN, NETHERLANDS--(MARKET WIRE)--Jul 25, 2007 -- Sittard/Leiden, The Netherlands, July 25, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell's technology to develop undisclosed antibodies. No financial details were disclosed.